Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML

Cell

Volumn 151, Issue 2, 2012, Pages 344-355

  Vo, Thanh Trang ^a,b   Ryan, Jeremy ^b   Carrasco, Ruben ^b   Neuberg, Donna ^b   Rossi, Derrick J ^a   Stone, Richard M ^b   Deangelo, Daniel J ^b   Frattini, Mark G ^c   Letai, Anthony ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BH3 PROTEIN; CLOFARABINE; CYTARABINE; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MITOCHONDRION; MYELOBLAST; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 84867490138     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.08.038     Document Type: Article

References (37)

1. F.R. Appelbaum, H. Gundacker, D.R. Head, M.L. Slovak, C.L. Willman, J.E. Godwin, J.E. Anderson, and S.H. Petersdorf Age and acute myeloid leukemia Blood 107 2006 3481 3485
2. J.K. Brunelle, and A. Letai Control of mitochondrial apoptosis by the Bcl-2 family J. Cell Sci. 122 2009 437 441
3. J.K. Brunelle, J. Ryan, D. Yecies, J.T. Opferman, and A. Letai MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts J. Cell Biol. 187 2009 429 442
4. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, S.A. Armstrong, and A. Letai Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members Cancer Cell 9 2006 351 365
5. L. Chen, S.N. Willis, A. Wei, B.J. Smith, J.I. Fletcher, M.G. Hinds, P.M. Colman, C.L. Day, J.M. Adams, and D.C. Huang Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function Mol. Cell 17 2005 393 403
6. E.H. Cheng, M.C. Wei, S. Weiler, R.A. Flavell, T.W. Mak, T. Lindsten, and S.J. Korsmeyer BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis Mol. Cell 8 2001 705 711
7. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) Biochem. Biophys. Res. Commun. 197 1993 40 45
8. N.N. Danial, and S.J. Korsmeyer Cell death: critical control points Cell 116 2004 205 219
9. J. Deng, N. Carlson, K. Takeyama, P. Dal Cin, M. Shipp, and A. Letai BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents Cancer Cell 12 2007 171 185
10. H. Döhner, E.H. Estey, S. Amadori, F.R. Appelbaum, T. Büchner, A.K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R.A. Larson European LeukemiaNet Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474
11. H.F. Fernandez, Z. Sun, X. Yao, M.R. Litzow, S.M. Luger, E.M. Paietta, J. Racevskis, G.W. Dewald, R.P. Ketterling, and J.M. Bennett Anthracycline dose intensification in acute myeloid leukemia N. Engl. J. Med. 361 2009 1249 1259
12. E. Gavathiotis, M. Suzuki, M.L. Davis, K. Pitter, G.H. Bird, S.G. Katz, H.C. Tu, H. Kim, E.H. Cheng, N. Tjandra, and L.D. Walensky BAX activation is initiated at a novel interaction site Nature 455 2008 1076 1081
13. R.M. Kluck, E. Bossy-Wetzel, D.R. Green, and D.D. Newmeyer The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis Science 275 1997 1132 1136
14. M. Konopleva, R. Contractor, T. Tsao, I. Samudio, P.P. Ruvolo, S. Kitada, X. Deng, D. Zhai, Y.X. Shi, and T. Sneed Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia Cancer Cell 10 2006 375 388
15. T. Kuwana, L. Bouchier-Hayes, J.E. Chipuk, C. Bonzon, B.A. Sullivan, D.R. Green, and D.D. Newmeyer BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly Mol. Cell 17 2005 525 535
16. F. Lacombe, F. Durrieu, A. Briais, P. Dumain, F. Belloc, E. Bascans, J. Reiffers, M.R. Boisseau, and P. Bernard Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia Leukemia 11 1997 1878 1886
17. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick A cell initiating human acute myeloid leukaemia after transplantation into SCID mice Nature 367 1994 645 648
18. A.G. Letai Diagnosing and exploiting cancer's addiction to blocks in apoptosis Nat. Rev. Cancer 8 2008 121 132
19. A. Letai, M.C. Bassik, L.D. Walensky, M.D. Sorcinelli, S. Weiler, and S.J. Korsmeyer Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics Cancer Cell 2 2002 183 192
20. R. Majeti, C.Y. Park, and I.L. Weissman Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood Cell Stem Cell 1 2007 635 645
21. K. Mrózek, N.A. Heerema, and C.D. Bloomfield Cytogenetics in acute leukemia Blood Rev. 18 2004 115 136
22. T. Ni Chonghaile, K.A. Sarosiek, T.T. Vo, J.A. Ryan, A. Tammareddi, Vdel.G. Moore, J. Deng, K.C. Anderson, P. Richardson, and Y.T. Tai Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy Science 334 2011 1129 1133
23. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat. Rev. Cancer 9 2009 338 350
24. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, and P.J. Hajduk An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 435 2005 677 681
25. J.T. Opferman, A. Letai, C. Beard, M.D. Sorcinelli, C.C. Ong, and S.J. Korsmeyer Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 Nature 426 2003 671 676
26. J.T. Opferman, H. Iwasaki, C.C. Ong, H. Suh, S. Mizuno, K. Akashi, and S.J. Korsmeyer Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells Science 307 2005 1101 1104
27. A.W. Roberts, J.F. Seymour, J.R. Brown, W.G. Wierda, T.J. Kipps, S.L. Khaw, D.A. Carney, S.Z. He, D.C. Huang, and H. Xiong Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease J. Clin. Oncol. 30 2012 488 496
28. J.A. Ryan, J.K. Brunelle, and A. Letai Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes Proc. Natl. Acad. Sci. USA 107 2010 12895 12900
29. R.F. Schlenk, K. Döhner, J. Krauter, S. Fröhling, A. Corbacioglu, L. Bullinger, M. Habdank, D. Späth, M. Morgan, A. Benner German-Austrian Acute Myeloid Leukemia Study Group Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N. Engl. J. Med. 358 2008 1909 1918
30. M.A. Sekeres, and R. Stone Older adults with acute myeloid leukemia Curr. Oncol. Rep. 4 2002 403 409
31. C. Tse, A.R. Shoemaker, J. Adickes, M.G. Anderson, J. Chen, S. Jin, E.F. Johnson, K.C. Marsh, M.J. Mitten, and P. Nimmer ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res. 68 2008 3421 3428
32. M.F. van Delft, A.H. Wei, K.D. Mason, C.J. Vandenberg, L. Chen, P.E. Czabotar, S.N. Willis, C.L. Scott, C.L. Day, and S. Cory The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized Cancer Cell 10 2006 389 399
33. M.C. Wei, T. Lindsten, V.K. Mootha, S. Weiler, A. Gross, M. Ashiya, C.B. Thompson, and S.J. Korsmeyer tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c Genes Dev. 14 2000 2060 2071
34. M.C. Wei, W.X. Zong, E.H. Cheng, T. Lindsten, V. Panoutsakopoulou, A.J. Ross, K.A. Roth, G.R. MacGregor, C.B. Thompson, and S.J. Korsmeyer Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death Science 292 2001 727 730
35. S.N. Willis, L. Chen, G. Dewson, A. Wei, E. Naik, J.I. Fletcher, J.M. Adams, and D.C. Huang Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins Genes Dev. 19 2005 1294 1305
36. W.H. Wilson, O.A. O'Connor, M.S. Czuczman, A.S. LaCasce, J.F. Gerecitano, J.P. Leonard, A. Tulpule, K. Dunleavy, H. Xiong, and Y.L. Chiu Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity Lancet Oncol. 11 2010 1149 1159
37. H. Zou, Y. Li, X. Liu, and X. Wang An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9 J. Biol. Chem. 274 1999 11549 11556